In last trading session, Transmedics Group Inc (NASDAQ:TMDX) saw 0.79 million shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $109.88 trading at -$2.64 or -2.35% at ring of the bell on the day assigns it a market valuation of $3.72B. That closing price of TMDX’s stock is at a discount of -61.42% from its 52-week high price of $177.37 and is indicating a premium of 49.95% from its 52-week low price of $55.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.9 million shares which gives us an average trading volume of 979.66K if we extend that period to 3-months.
For Transmedics Group Inc (TMDX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.70. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.43 in the current quarter.
Transmedics Group Inc (NASDAQ:TMDX) trade information
Transmedics Group Inc’s shares saw a change of -27.62% in year-to-date performance and have moved -2.29% in past 5-day. Transmedics Group Inc (NASDAQ:TMDX) showed a performance of -19.32% in past 30-days. Number of shares sold short was 7.86 million shares which calculate 9.46 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 114.5 to the stock, which implies a rise of 4.03% to its current value. Analysts have been projecting 45 as a low price target for the stock while placing it at a high target of 151. It follows that stock’s current price would jump 59.05% in reaching the projected high whereas dropping to the targeted low would mean a gain of 59.05% for stock’s current value.
Transmedics Group Inc (TMDX) estimates and forecasts
This year revenue growth is estimated to rise 31.34% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 146.64M for the same. And 8 analysts are in estimates of company making revenue of 140.81M in the next quarter. Company posted 114.31M and 108.76M of sales in current and next quarters respectively a year earlier. In 2025, company’s earnings growth rate is likely to be around 83.27% while estimates for its earnings growth in next 5 years are of 48.07%.
Transmedics Group Inc (NASDAQ:TMDX)’s Major holders
Insiders are in possession of 3.03% of company’s total shares while institution are holding 121.56 percent of that, with stock having share float percentage of 125.36%. Investors also watch the number of corporate investors in a company very closely, which is 121.56% institutions for Transmedics Group Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at TMDX for having 4.49 million shares of worth $676.31 million. And as of 2024-06-30, it was holding 13.5576 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 2.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9879 of outstanding shares, having a total worth of $398.47 million.
On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of May 31, 2025 , the former fund manager was holding 2.02 shares of worth $221.63 million or 5.96% of the total outstanding shares. The later fund manager was in possession of 1.0 shares on Mar 31, 2025 , making its stake of worth around $110.38 million in the company or a holder of 2.97% of company’s stock.
